Helogen Raises $7.1M Seed Led by RRE Ventures for Orbital Biomanufacturing

Helogen Closes $7.1M Seed Round

Helogen, a New York-based space manufacturing company, has raised $7.1 million in Seed funding. The round was led by RRE Ventures and included participation from Oceans Ventures, One Way Ventures, and blisce/. The funding was announced on September 4, 2026.

What Helogen Does

Helogen is building autonomous orbital factories for high-value biomaterials. Its zero-crew HEL-IOS platform integrates biological cultivation, processing, and real-time analytics into a single closed-loop workflow. This platform is flown on Helogen's own spacecraft and partner orbital platforms such as Starlab.

The company produces protein polymers for orthopedic implants and regenerative medicine, while also serving biopharma and academic research customers. Helogen is already flying customer-funded and internal manufacturing missions in low-Earth orbit, including a partnership with LambdaVision to produce artificial-retina protein films outside the ISS.

A Proven Track Record

The HEL-IOS platform was the winner of the 2025 NASA TechLeap Prize, underscoring the technical validation of Helogen's approach to in-space biomanufacturing. The company's ability to conduct customer-funded missions demonstrates early commercial traction in a capital-intensive sector.

The Funding Details

• Round type: Seed
• Amount raised: $7,100,000
• Currency: USD
• Announced date: September 4, 2026
• Lead investor: RRE Ventures
• Additional investors: Oceans Ventures, One Way Ventures, blisce/

The syndicate includes deep-tech and venture investors, reflecting confidence in Helogen's niche at the intersection of space infrastructure and biotechnology.

Why This Matters for the Market

Orbital manufacturing represents a frontier opportunity for producing materials that are difficult or impossible to make on Earth. Microgravity conditions can enable superior protein crystal formation and biomaterial properties, which is particularly valuable for medical applications like orthopedic implants and regenerative medicine.

Helogen's closed-loop, zero-crew platform addresses a key challenge in space manufacturing: the need for autonomous, reliable production systems that do not rely on astronaut labor. By integrating cultivation, processing, and analytics, the company offers a turnkey solution for biopharma and research customers seeking to leverage the orbital environment.

Commercial and Strategic Positioning

The partnership with LambdaVision for artificial-retina protein films outside the ISS highlights Helogen's ability to execute on customer-funded missions. This commercial validation, combined with the NASA TechLeap Prize, positions Helogen as a credible player in the emerging space biomanufacturing market.

For acquisition-oriented observers, Helogen represents a rare asset: a space manufacturing company with proven flight hardware, commercial customers, and a clear application in high-value medical markets. The seed funding provides capital to scale operations and expand its orbital manufacturing capacity.

What's Next

With this funding, Helogen is poised to increase the frequency of its manufacturing missions and deepen partnerships with biopharma and academic customers. As demand for advanced biomaterials grows, orbital production could become a differentiated supply source for orthopedic and regenerative medicine products.